Prevalence Estimates of Predicted Pathogenic COL4A3–COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Significance Statement: The population frequencies of Alport syndrome vary greatly in different reports. This study examined a population sequencing database of individuals not known to have kidney disease using filtering steps corresponding to the American College of Medical Genetics and Genomics/Association for Molecular Pathology criteria for “predicted pathogenic” variants in COL4A3–COL4A5, which considered collagen chain position 1 Gly residues “critical domains.” Predicted pathogenic COL4A5 variants occurred in at least one in 2320 individuals. Heterozygous COL4A3 or COL4A4 variants affected one in 106; compound heterozygous COL4A3 or COL4A4 variants affected one in 88,866. The actual prevalences are even greater because they also include already diagnosed disease and other variants not examined here. The high frequency of predicted pathogenic COL4A3–COL4A5 variants suggests that other genetic and environmental factors mitigate the corresponding clinical manifestations of disease. Background: The reported prevalence of Alport syndrome varies from one in 5000 to one in 53,000 individuals. This study estimated the frequencies of predicted pathogenic COL4A3–COL4A5 variants in sequencing databases of populations without known kidney disease. Methods: Predicted pathogenic variants were identified using filtering steps based on the ACMG/AMP criteria, which considered collagen IV α 3–α 5 position 1 Gly to be critical domains. The population frequencies of predicted pathogenic COL4A3–COL4A5 variants were then determined per mean number of sequenced alleles. Population frequencies for compound heterozygous and digenic combinations were calculated from the results for heterozygous variants. Results: COL4A3–COL4A5 variants resulting in position 1 Gly substitutions were confirmed to be associated with hematuria (for each, P<0.001). Predicted pathogenic COL4A5 variants were found in at least one in 2320 individuals. p.(Gly624Asp) represented nearly half (16 of 33, 48%) of the variants in Europeans. Most COL4A5 variants (54 of 59, 92%) had a biochemical feature that potentially mitigated the clinical effect. The predicted pathogenic heterozygous COL4A3 and COL4A4 variants affected one in 106 of the population, consistent with the finding of thin basement membrane nephropathy in normal donor kidney biopsy specimens. Predicted pathogenic compound heterozygous variants occurred in one in 88,866 individuals, and digenic variants in at least one in 44,793. Conclusions: The population frequencies for Alport syndrome are suggested by the frequencies of predicted pathogenic COL4A3–COL4A5 variants, but must be adjusted for the disease penetrance of individual variants and for the likelihood of already diagnosed disease and non-Gly substitutions. Disease penetrance may depend on other genetic and environmental factors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion
Abou Tayoun, A. N., Pesaran, T., DiStefano, M. T., Oza, A., Rehm, H. L., Biesecker, L. G., Harrison, S. M., & ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI) (2018) · Human Mutation · doi:10.1002/humu.23626 · Cited by 885
Identification of Mutations in the COL4A5 Collagen Gene in Alport Syndrome
Barker, D. F., Hostikka, S. L., Zhou, J., Chow, L. T., Oliphant, A. R., Gerken, S. C., Gregory, M. C., Skolnick, M. H., Atkin, C. L., & Tryggvason, K. (1990) · Science · doi:10.1126/science.2349482 · Cited by 876
Diagnostic Utility of Exome Sequencing for Kidney Disease
Groopman, E. E., Marasa, M., Cameron-Christie, S., Petrovski, S., Aggarwal, V. S., Milo-Rasouly, H., Li, Y., Zhang, J., Nestor, J., Krithivasan, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806891 · Cited by 783
Collagens and collagen-related diseases
Myllyharju, J., & Kivirikko, K. I. (2001) · Annals of Medicine · doi:10.3109/07853890109002055 · Cited by 756
JAIS, J. P., KNEBELMANN, B., GIATRAS, I., MARCHI, M. D., RIZZONI, G., RENIERI, A., WEBER, M., GROSS, O., NETZER, K.-O., FLINTER, F., et al. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v114649 · Cited by 606
Mochizuki, T., Lemmink, H. H., Mariyama, M., Antignac, C., Gubler, M.-C., Pirson, Y., Verellen-Dumoulin, C., Chan, B., Schröder, C. H., Smeets, H. J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-77 · Cited by 511
Jais, J. P., Knebelmann, B., Giatras, I., De Marchi, M., Rizzoni, G., Renieri, A., Weber, M., Gross, O., Netzer, K.-O., Flinter, F., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000090034.71205.74 · Cited by 482
Amino Acid Propensities for the Collagen Triple-Helix
Persikov, A. V., Ramshaw, J. A. M., Kirkpatrick, A., & Brodsky, B. (2000) · Biochemistry · doi:10.1021/bi001560d · Cited by 395
Self-citationGross, O., Licht, C., Anders, H. J., Hoppe, B., Beck, B., Tönshoff, B., Höcker, B., Wygoda, S., Ehrich, J. H. H., Pape, L., et al. (2012) · Kidney International · doi:10.1038/ki.2011.407 · Cited by 371 · cited 1×
“Affected women often have only hematuria, but identifying affectedwomen is still important because of their own risk of end stage kidney failure, because half of their sons develop kidney failure,(22) and because treatment is effective.(51) Most other COL4A5 variants identified in gnomAD were associated with a clinica…”
BackgroundKelly, M. A., Caleshu, C., Morales, A., Buchan, J., Wolf, Z., Harrison, S. M., Cook, S., Dillon, M. W., Garcia, J., Haverfield, E., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.218 · Cited by 364
Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing
Lanktree, M. B., Haghighi, A., Guiard, E., Iliuta, I.-A., Song, X., Harris, P. C., Paterson, A. D., & Pei, Y. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050493 · Cited by 300 · cited 1×
“A similar approach has been used previously to determine the population frequency of polycystic kidney and liver disease.(31) We then identified predicted pathogenic COL4A3 and COL4A4 variants in gnomAD, and used these to calculate the frequencies of compound heterozygous and digenic variants.”
MethodGenotype–Phenotype Correlation in X-Linked Alport Syndrome
Bekheirnia, M. R., Reed, B., Gregory, M. C., McFann, K., Shamshirsaz, A. A., Masoumi, A., & Schrier, R. W. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070784 · Cited by 279
The ACMG/AMP reputable source criteria for the interpretation of sequence variants
Biesecker, L. G., & Harrison, S. M. (2018) · Genetics in Medicine · doi:10.1038/gim.2018.42 · Cited by 276
Proteinuria and hematuria in schoolchildren: Epidemiology and early natural history
Dodge, W. F., West, E. F., Smith, E. H., & Bunce, H. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)81012-8 · Cited by 231
Voskarides, K., Damianou, L., Neocleous, V., Zouvani, I., Christodoulidou, S., Hadjiconstantinou, V., Ioannou, K., Athanasiou, Y., Patsias, C., Alexopoulos, E., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007040444 · Cited by 209 · cited 1×
“In addition, any variant or combination of variants in COL4A3– COL4A5 may result in FSGS, probably secondary to a defective GBM and podocyte loss.(9,10) Alport syndrome has been considered rare because it affects fewer than one in 2000 individuals,(11) and the United States has,200,000 patients with Alport syndrome.”
Backgroundvan der Ven, A. T., Connaughton, D. M., Ityel, H., Mann, N., Nakayama, M., Chen, J., Vivante, A., Hwang, D.-Y., Schulz, J., Braun, D. A., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121265 · Cited by 204 · cited 2×
“Variants that occurred in gnomAD at an arbitrary cutoff of ,30 timeswere gradedPM2.(34) The formula used todetermine the cutoff is normally based on the disease prevalence and contribution of the gene, which were not known.”
MethodExpert consensus guidelines for the genetic diagnosis of Alport syndrome
Savige, J., Ariani, F., Mari, F., Bruttini, M., Renieri, A., Groß, O., Deltas, C. C., Flinter, F. A., Ding, J., Gale, D. P., et al. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3985-4 · Cited by 171 · cited 1×
“The most sensitive method for the diagnosis of Alport syndrome is genetic testing(19,23) using massively parallel sequencing, which detects causative variants in up to 90% of individuals.(23) Identifying likely pathogenic variants in the COL4A3–COL4A5 genes in datasets of individuals not known to have kidney disease—u…”
MethodSelf-citationEvidence of digenic inheritance in Alport syndrome
Mencarelli, M. A., Heidet, L., Storey, H., van Geel, M., Knebelmann, B., Fallerini, C., Miglietti, N., Antonucci, M. F., Cetta, F., Sayer, J. A., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102822 · Cited by 163 · cited 2×
“Digenic Alport syndrome occurs with heterozygous pathogenic variants in two different COL4A3– COL4A5 genes,(8) and clinical features may be more severe than with only a heterozygous COL4A3 or COL4A4 variant.(8) In addition, any variant or combination of variants in COL4A3– COL4A5 may result in FSGS, probably secondary…”
BackgroundSelf-citationPierides, A., Voskarides, K., Athanasiou, Y., Ioannou, K., Damianou, L., Arsali, M., Zavros, M., Pierides, M., Vargemezis, V., Patsias, C., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp158 · Cited by 162
Gross, O., Tönshoff, B., Weber, L. T., Pape, L., Latta, K., Fehrenbach, H., Lange-Sperandio, B., Zappel, H., Hoyer, P., Staude, H., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.12.015 · Cited by 160
Bullich, G., Domingo-Gallego, A., Vargas, I., Ruiz, P., Lorente-Grandoso, L., Furlano, M., Fraga, G., Madrid, Á., Ariceta, G., Borregán, M., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.02.027 · Cited by 159
Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport syndrome.
Knebelmann, B., Breillat, C., Forestier, L., Arrondel, C., Jacassier, D., Giatras, I., Drouot, L., Deschênes, G., Grünfeld, J., Broyer, M., et al. (1996) · PubMed · Cited by 153
Savige, J., Storey, H., Watson, E., Hertz, J. M., Deltas, C. C., Renieri, A., Mari, F., Hilbert, P., Plevová, P., Byers, P. H., et al. (2021) · European Journal of Human Genetics · doi:10.1038/s41431-021-00858-1 · Cited by 145 · cited 1×
“The most common reported missense variants in COL4A3–COL4A5 result in position 1 Gly substitutions in the intermediate domain of the collagen IV a3, a4, and a5 chains,(12,25) and the recent Chandos House meeting of the Alport Variant Consortium recommended that these are generally considered pathogenic.(26) There are,…”
BackgroundSelf-citationMariyama, M., Leinonen, A., Mochizuki, T., Tryggvason, K., & Reeders, S. T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31612-5 · Cited by 127
Persikov, A. V., Pillitteri, R. J., Amin, P., Schwarze, U., Byers, P. H., & Brodsky, B. (2004) · Human Mutation · doi:10.1002/humu.20091 · Cited by 106 · cited 1×
“Mitigating features included female sex(22); location within the 20 amino-terminal exons including the amino noncollagenous domain (204 residues)(39); position adjacent to a noncollagenous domain or interruption(30); and Gly substitutionswith a less disruptive residue, such as alanine (Ala), serine (Ser), or cysteine…”
BackgroundSelf-citationSavige, J., Storey, H., Cheong, H. I., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161802 · Cited by 105 · cited 1×
“Mitigating features included female sex(22); location within the 20 amino-terminal exons including the amino noncollagenous domain (204 residues)(39); position adjacent to a noncollagenous domain or interruption(30); and Gly substitutionswith a less disruptive residue, such as alanine (Ala), serine (Ser), or cysteine…”
BackgroundSelf-citationStructural Heterogeneity of Type I Collagen Triple Helix and Its Role in Osteogenesis Imperfecta
Makareeva, E., Mertz, E. L., Kuznetsova, N. V., Sutter, M. B., DeRidder, A. M., Cabral, W. A., Barnes, A. M., McBride, D. J., Marini, J. C., & Leikin, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705773200 · Cited by 101 · cited 1×
“However, some position 1 Gly substitutions in COL4A3–COL4A5 were not considered pathogenic, and assertions from collagen I variants in osteogenesis imperfecta suggest that nearby amino acids determinewhether chainflexibility from a non-Gly substitution is tolerated.(50) The gnomAD and TOPMed datasets represented cohor…”
BackgroundLeinonen, A., Mariyama, M., Mochizuki, T., Tryggvason, K., & Reeders, S. T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47174-8 · Cited by 99
Mutations in the COL4A4 gene in thin basement membrane disease
Buzza, M., Dagher, H., Wang, Y., Wilson, D., Babon, J. J., Cotton, R. G. H., & Savige, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00780.x · Cited by 75
Self-citationAlport syndrome: impact of digenic inheritance in patients management
Fallerini, C., Baldassarri, M., Trevisson, E., Morbidoni, V., Manna, A. L., Lazzarin, R., Pasini, A., Barbano, G., Pinciaroli, A. R., Garosi, G., et al. (2016) · Clinical Genetics · doi:10.1111/cge.12919 · Cited by 65 · cited 1×
“The prevalence of AR Alport syndrome due to compound heterozygous variants and of digenic Alport syndrome is probably affected less because hematuria and renal impairment are more likely with two COL4A3–COL4A5 variants.(8,49) Genetic testing is the most sensitive method for the detection ofCOL4A3–5 variants and, hence…”
BackgroundPodocyte Depletion in Thin GBM and Alport Syndrome
Wickman, L. T., Hodgin, J. B., Wang, S. Q., Afshinnia, F., Kershaw, D. S., & Wiggins, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155255 · Cited by 51 · cited 1×
“In addition, any variant or combination of variants in COL4A3– COL4A5 may result in FSGS, probably secondary to a defective GBM and podocyte loss.(9,10) Alport syndrome has been considered rare because it affects fewer than one in 2000 individuals,(11) and the United States has,200,000 patients with Alport syndrome.”
BackgroundZurowska, A. M., Bielska, O., Daca‐Roszak, P., Jankowski, M., Szczepańska, M., Roszkowska-Bjanid, D., Kuźma-Mroczkowska, E., Pańczyk-Tomaszewska, M., Moczulska, A., Drożdż, D., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.10.040 · Cited by 50
Genetics in an isolated population like Finland: a different basis for genomic medicine?
Kääriäinen, H., Muilu, J., Perola, M., & Kristiansson, K. (2017) · Journal of Community Genetics · doi:10.1007/s12687-017-0318-4 · Cited by 45 · cited 1×
“It may not be thatCOL4A3–COL4A5 variants aremore common in some ancestries, but rather that they are uncommon in others due to geographic and cultural isolation.(52) In conclusion, predicted pathogenic COL4A5 variants occur in at least one in 2320 of the population, but are often unrecognized.”
BackgroundA two-tier approach to mutation detection in theCOL4A5 gene for Alport syndrome
King, K., Flinter, F. A., & Green, P. M. (2006) · Human Mutation · doi:10.1002/humu.9453 · Cited by 20
Macheroux, E. P., Braunisch, M. C., Pegler, S. P., Satanovskij, R. M., Riedhammer, K. M., Günthner, R., Groß, O., Nagel, M., Renders, L., & Hoefele, J. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00485 · Cited by 16
Response to Biesecker and Harrison
Richards, C. S., Aziz, N., Bale, S. J., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2018.43 · Cited by 7
Metadata
- Authors
- Gibson, J., Fieldhouse, R., Chan, M. M. Y., Sadeghi-Alavijeh, O., Burnett, L., Izzi, V., Persikov, A. V., Gale, D. P., Storey, H., Savige, J., & on behalf of the Genomics England Research Consortium
- Venue
- Journal of the American Society of Nephrology
- Published
- 2021-09
- Volume
- 32
- Issue
- 9
- Pages
- 2273-2290
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W3173220290
- Cited by
- 218
- References
- 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.